CTSS and aneurysm: In addition, the altered levels of CTSs and their endogenous inhibitors in patients with ACVD, aneurysm, obesity, diabetes mellitus, and peripheral arterial disease indicate that these molecules can also serve as diagnostic biomarkers of ACVDs [2, 13].